Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling Y Zhuang, H Liu, X Edward Zhou, R Kumar Verma, PW de Waal, W Jang, ... Nature communications 11 (1), 885, 2020 | 94 | 2020 |
Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor M Michino, CA Boateng, P Donthamsetti, H Yano, OM Bakare, A Bonifazi, ... Journal of medicinal chemistry 60 (2), 580-593, 2017 | 54 | 2017 |
MIPModDB: a central resource for the superfamily of major intrinsic proteins AB Gupta, RK Verma, V Agarwal, M Vajpai, V Bansal, ... Nucleic acids research 40 (D1), D362-D369, 2012 | 50 | 2012 |
Gs- versus Golf-dependent functional selectivity mediated by the dopamine D1 receptor H Yano, NS Cai, M Xu, RK Verma, W Rea, AF Hoffman, L Shi, JA Javitch, ... Nature communications 9 (1), 486, 2018 | 47 | 2018 |
A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity M Sanchez-Soto, RK Verma, BKA Willette, EC Gonye, AM Moore, ... Science signaling 13 (617), eaaw5885, 2020 | 36 | 2020 |
New subfamilies of major intrinsic proteins in fungi suggest novel transport properties in fungal channels: implications for the host-fungal interactions RK Verma, ND Prabh, R Sankararamakrishnan BMC evolutionary biology 14, 1-16, 2014 | 33 | 2014 |
Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism JR Lane, AM Abramyan, P Adhikari, AC Keen, KH Lee, J Sanchez, ... Elife 9, e52189, 2020 | 32 | 2020 |
The structural determinants of the bitopic binding mode of a negative allosteric modulator of the dopamine D2 receptor CJ Draper-Joyce, M Michino, RK Verma, CK Herenbrink, J Shonberg, ... Biochemical pharmacology 148, 315-328, 2018 | 28 | 2018 |
Major intrinsic protein superfamily: channels with unique structural features and diverse selectivity filters RK Verma, AB Gupta, R Sankararamakrishnan Methods in Enzymology 557, 485-520, 2015 | 27 | 2015 |
Molecular determinants of the intrinsic efficacy of the antipsychotic aripiprazole C Klein Herenbrink, R Verma, HD Lim, A Kopinathan, A Keen, J Shonberg, ... ACS chemical biology 14 (8), 1780-1792, 2019 | 24 | 2019 |
The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors RK Verma, AM Abramyan, M Michino, RB Free, DR Sibley, JA Javitch, ... PLoS Computational Biology 14 (1), e1005948, 2018 | 20 | 2018 |
Intra-helical salt-bridge and helix destabilizing residues within the same helical turn: Role of functionally important loop E half-helix in channel regulation of major … RK Verma, ND Prabh, R Sankararamakrishnan Biochimica et Biophysica Acta (BBA)-Biomembranes 1848 (6), 1436-1449, 2015 | 20 | 2015 |
Infigratinib is a reversible inhibitor and mechanism-based inactivator of cytochrome P450 3A4 LWT Tang, JW Teng, RK Verma, SK Koh, L Zhou, ML Go, H Fan, ... Drug Metabolism and Disposition 49 (9), 856-868, 2021 | 18 | 2021 |
The action of a negative allosteric modulator at the dopamine D2 receptor is dependent upon sodium ions CJ Draper-Joyce, RK Verma, M Michino, J Shonberg, A Kopinathan, ... Scientific Reports 8 (1), 1208, 2018 | 16 | 2018 |
Recent advances in structure, function, and pharmacology of class A lipid GPCRs: opportunities and challenges for drug discovery RNV Krishna Deepak, RK Verma, YD Hartono, WS Yew, H Fan Pharmaceuticals 15 (1), 12, 2021 | 14 | 2021 |
Mechanism-based inactivation of cytochrome P450 3A4 by benzbromarone LWT Tang, RK Verma, H Fan, ECY Chan Molecular Pharmacology 99 (4), 266-276, 2021 | 14 | 2021 |
Evidence for a Stereoselective Mechanism for Bitopic Activity by Extended-Length Antagonists of the D3 Dopamine Receptor AE Moritz, A Bonifazi, AM Guerrero, V Kumar, RB Free, JR Lane, ... ACS chemical neuroscience 11 (20), 3309-3320, 2020 | 14 | 2020 |
Direct and sequential bioactivation of pemigatinib to reactive iminium ion intermediates culminates in mechanism-based inactivation of cytochrome P450 3A LWT Tang, W Wei, RK Verma, SK Koh, L Zhou, H Fan, ECY Chan Drug Metabolism and Disposition 50 (5), 529-540, 2022 | 12 | 2022 |
Atypical kinetics of cytochrome P450 2J2: epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors JWH Leow, RK Verma, ABH Lim, H Fan, ECY Chan European Journal of Pharmaceutical Sciences 164, 105889, 2021 | 10 | 2021 |
Differential reversible and irreversible interactions between benzbromarone and human cytochrome P450s 3A4 and 3A5 LWT Tang, RK Verma, RP Yong, X Li, L Wang, Q Lin, H Fan, ECY Chan Molecular Pharmacology 100 (3), 224-236, 2021 | 8 | 2021 |